Simplify's take
What believers are saying
- Pascall won over $13.6 million NIH funding for anesthesia personalization.
- October 2026 website updates show active commercialization and conference visibility.
- The FDA-cleared PSU1 can now convert research credibility into hospital pilots fast.
What critics are saying
- Revenue still depends on hospital procurement after August 2026 clearance.
- Incumbents like Masimo and Medtronic already own operating-room monitoring workflows.
- Single-product dependence makes an adverse FDA complaint or recall existential.
What makes PASCALL Systems unique
- August 2026 FDA clearance lets Pascall sell a wireless forehead EEG monitor.
- The PSU1 patch combines electrodes, batteries, and BLE into one disposable sensor.
- Wireless bedside EEG with age-scaled displays targets anesthesiologists needing real-time brain monitoring.
Help us improve and share your feedback! Did you find this helpful?